PTC Therapeutics, Inc.
PTCT
$46.41
-$0.53-1.13%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -30.58% | 0.11% | -12.68% | -4.66% | 83.41% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -30.58% | 0.11% | -12.68% | -4.66% | 83.41% |
| Cost of Revenue | -6.26% | -0.83% | -25.63% | -37.46% | -24.61% |
| Gross Profit | -53.94% | 7.24% | 156.58% | 613.06% | 586.67% |
| SG&A Expenses | 11.00% | -9.19% | -21.42% | -15.70% | -17.72% |
| Depreciation & Amortization | -95.71% | -94.82% | -93.96% | 30.74% | 115.79% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -24.64% | -20.59% | -34.20% | -23.82% | -7.36% |
| Operating Income | -608.69% | 55.46% | 72.35% | 60.46% | 101.94% |
| Income Before Tax | 39.70% | 41.18% | 63.90% | 37.26% | 17.21% |
| Income Tax Expenses | -2,188.56% | 125.77% | 134.84% | 73.34% | 93.30% |
| Earnings from Continuing Operations | 57.71% | 19.79% | 50.13% | 34.10% | 8.83% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 57.71% | 19.79% | 50.13% | 34.10% | 8.83% |
| EBIT | -608.69% | 55.46% | 72.35% | 60.46% | 101.94% |
| EBITDA | -110.86% | 16.72% | 62.18% | 113.60% | 168.83% |
| EPS Basic | 58.65% | 21.40% | 51.43% | 36.48% | 12.26% |
| Normalized Basic EPS | 283.87% | 38.65% | 50.02% | 38.73% | 85.22% |
| EPS Diluted | 58.65% | 21.40% | 51.43% | 36.48% | 12.43% |
| Normalized Diluted EPS | 283.87% | 38.65% | 50.02% | 38.73% | 85.22% |
| Average Basic Shares Outstanding | 2.27% | 2.05% | 2.67% | 3.75% | 3.90% |
| Average Diluted Shares Outstanding | 2.27% | 2.05% | 2.67% | 3.75% | 3.90% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |